GlassScriptPhysician profile
Audrey B Cross
NPI 1326763103
$1,207.46
in general payments reported to CMS, 2019-2025
15 companies · $356 in 2025
The $356 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $26.83 · 2023: $389 · 2024: $436 · 2025: $356.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,181.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,180.63 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sumitomo Pharma America, INC. | $326.22 | 2023-2025 | Myfembree, Gemtesa |
| Astellas Pharma US INC | $240.08 | 2023-2025 | Veozah, Myrbetriq |
| Organon LLC | $172.73 | 2023-2024 | Nexplanon |
| Boston Scientific Corporation | $76.39 | 2025 | General - Female Sui |
| Exeltis, USA INC. | $61.64 | 2024-2025 | Slynd |
| Abbvie INC. | $55.85 | 2023-2024 | |
| Mayne Pharma Commercial LLC | $51.50 | 2022-2025 | |
| Daiichi Sankyo INC. | $51.03 | 2023 | Injectafer |
| Pfizer INC. | $46.84 | 2023-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $30.75 | 2023-2025 | |
| Merck Sharp & Dohme LLC | $29.81 | 2025 | Keytruda Qlex, Keytruda |
| Axonics, INC. | $22.77 | 2024 | Bulkamid, Axonics |
| Dexcom, INC. | $14.38 | 2024 | Dexcom G6 Transmitter |
| Exact Sciences Corporation | $14.30 | 2025 | The Cologuard Plus Collection Kit |
| Myovant Sciences INC. | $13.17 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Audrey Cross listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.